A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Completed · Phase 3

Conditions studied: Prostate Cancer

In brief

This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.

Key facts

Study ID
NCT00036543
Run by
Abbott
People needed
1000
Starts
2001-05-01
Last updated by the study team
2006-08-15

Who can join

Age: 19 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.